Share this article
Share this article
HAIFA, Israel, Feb. 1, 2021 /PRNewswire/ ZIM Integrated Shipping Services Ltd. (NYSE: ZIM) (the Company ), a global container liner shipping company with over 75 years of experience, announced today the closing of its initial public offering ( IPO ) of 14,500,000 ordinary shares, at a price to the public of $15.00 per ordinary share, for gross proceeds of $217.5 million, before deducting underwriting discounts and commissions or other offering expenses.
The ordinary shares began trading on The New York Stock Exchange (the NYSE ) under the symbol ZIM on January 28, 2021.
Citigroup, Goldman Sachs & Co., LLC., and Barclays acted as global coordinators and Jefferies and Clarksons Platou Securities acted as joint bookrunners for the proposed initial public offering.
(2)
Includes the Early Tender Premium (as defined below).
The Tender Offer will expire at 11:59 p.m., New York City time, on March 1, 2021, or any other date and time to which Volcan extends the Tender Offer (such date and time, as it may be extended, the
Expiration Date ), unless earlier terminated. Holders must validly tender their Notes at or prior to the Expiration Date to be eligible to receive the Tender Offer Consideration (as defined below) for such Notes plus Accrued Interest (as defined below). Holders must validly tender their Notes at or prior to 5:00 p.m., New York City time, on February 12, 2021 (such date and time, as it may be extended, the
Horizon Therapeutics plc (NASDAQ: HZNP) and
Viela Bio, Inc. (NASDAQ: VIE) have entered into a definitive agreement where Horizon will acquire all issues and outstanding shares of Vielo Bio common stock for USD 53 per share in cash or a fully diluted equity value of USD 3.05 Billion. The transaction is expected to close by the end of the first quarter of 2021. “This acquisition represents a significant step forward in advancing our strategy – to expand our pipeline in order to accelerate our growth over the long term,” said Tim Walbert, chairman, president and chief executive officer, Horizon. “Adding Viela’s research and clinical development capabilities along with its deep, mid-stage biologics pipeline to our seasoned R&D and commercial teams, advances our transformation to an innovation-driven biotech company where we will build on the success of TEPEZZA and KRYSTEXXA to bolster our long-term growth trajectory. We intend to maximize the full potential of Viela’s
29.01.2021 - Northern Star Investment Corp. II (the “Company”) announced today that it consummated its upsized initial public offering of 40,000,000 units, including 5,000,000 units subject to the underwriters’ over-allotment option, at $10.00 per unit. The .